Abstract: The invention relates to novel dibenzo[1,2;5,6]cyclohepta pyridine or -pyrrole derivatives, dibenzo[2,3;6,7]oxepino pyridine or pyrrole derivatives, dibenzo[2,3;6,7]thiepino pyridine or pyrrole derivatives and dibenzo[b,f]pyrido or pyrrolo azepine derivatives of general formula: ##STR1## as well as the pharmaceutically acceptable salts and nitrogen oxides thereof, whereinR.sub.1, r.sub.2, r.sub.3 and R.sub.4 each represent hydrogen, hydroxy, halogen, an alkyl (1-6 C) group, an alkoxy or alkylthio group in which the alkyl group contains 1-6 C-atoms, or a trifluoromethyl group,R.sub.5 represents hydrogen, an alkyl group with 1-6 carbon atoms or an aralkyl group with 7-10 carbon atoms,M is the number 1 or 2,X represents oxygen, sulphur, the group ##STR2## OR THE GROUP --CH.sub.2 -- and R.sub.6 represents hydrogen or a lower alkyl group (1-4 C),having CNS-depressant activity and excellent antihistamine and antiserotonin activities.

Abstract: The invention relates to novel dibenzo[1,2;5,6] cyclohepta pyridine or -pyrrole derivatives, dibenzo[2,3;6,7] oxepino pyridine or pyrrole derivatives, dibenzo[2,3;6,7] thiepino pyridine or pyrrole derivatives and dibenzo[b,f] pyrido or pyrrolo azepine derivatives of general formula: ##STR1## as well as the pharmaceutically acceptable salts and nitrogen oxides thereof, whereinR.sub.1, r.sub.2, r.sub.3 and R.sub.4 each represent hydrogen, hydroxy, halogen, an alkyl (1-6 C) group, an alkoxy or alkylthio group in which the alkyl group contains 1-6 C-atoms, or a trifluoromethyl group,R.sub.5 represents hydrogen, an alkyl group with 1-6 carbon atoms or an aralkyl group with 7-10 carbon atoms,M is the number 1 or 2,X represents oxygen, sulphur, the group ##STR2## or the group --CH.sub.2 -- and R.sub.6 represents hydrogen or a lower alkyl group (1-4 C),having CNS-depressant activity and excellent antihistamine and antiserotonin activities.

Abstract: The present invention relates to novel benzo(b) bicyclo[3.3.1]nones of the general formula I: ##STR1## and a salt or nitrogen oxide thereof, in which R.sub.1 and R.sub.2 stand for hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 1-6 carbon atoms, an optionally substituted aralkyl group or an acyl group orR.sub.1 and R.sub.2 together with the nitrogen atom represent a heterocyclic 5- or 6-membered ringR.sub.3 is a free, etherified or esterified hydroxy,X and Y stand for hydrogen, hydroxy, halogen, alkyl or alkoxy of 1-6 C-atoms, nitro, CF.sub.3 or an acyloxy group, having valuable biological activities, particularly anorectic activity.

Abstract: The invention relates to novel dibenzo[1,2;5,6]cyclohepta pyridine or -pyrrole derivatives, dibenzo[2,3;6,7]oxepino pyridine or pyrrole derivatives, dibenzo[2,3;6,7]thiepino pyridine or pyrrole derivatives and dibenzo[b,f]pyrido or pyrrolo azepine derivatives of general formula: ##STR1## as well as the pharmaceutically acceptable salts and nitrogen oxides thereof, whereinR.sub.1, r.sub.2, r.sub.3 and R.sub.4 each represent hydrogen, hydroxy, halogen, an alkyl (1-6 C) group, an alkoxy or alkylthio group in which the alkyl group contains 1-6 C-atoms, or a trifluoromethyl group,R.sub.5 represents hydrogen, an alkyl group with 1-6 carbon atoms or an aralkyl group with 7-10 carbon atoms,M is the number 1 or 2,X represents oxygen, sulphur, the group ##STR2## or the group --CH.sub.2 -- and R.sub.6 represents hydrogen or a lower alkyl group (1-4 C),having CNS-depressant activity and excellent antihistamine and antiserotonin activities.

Abstract: A new and remarkably stable synthesized conjugated estrogen composition comprising one or more selected alkali metal synthetic conjugated estrogen sulfate salts and an effective amount of one or more suitable antioxidants has been found for use in novel and stable therapeutic preparations of a pH of not less than about 7 which are adapted to relieve, inter alia, complaints occurring in the menopausal syndrome and other female complaints. Preferably, the steroids are selected from the sodium and potassium salts of the group consisting of estrone, equilin, 17.alpha.-dihydroequilin, and mixtures or conjugates thereof. Most preferably, the preparations are so formulated so that sodium estrone sulfate, sodium equilin sulphate, and 17.alpha.-dihydroequilin sodium sulphate as conjugated estrogens are present in a weight ratio of about 6:3:1, respectively and administered in tablets containing 0.625 mg, 1.25 mg, or 2.5 mg of total conjugated estrogens.

Abstract: A new diagnostic labeled spine tool is disclosed for use in immunoassay techniques, e.g., determination of a component of the antigen-antibody reaction. The new tool is a labeled-spine material product of the formula ##STR1## where R is an organic group labeled with a radioisotope, fluorescent group, lysis-initiating compound, enzyme, or other suitable marker material; T.sub.1 and T.sub.2 are any of --CH.sub.3, ##STR2## --CH.sub.2 OH, --Ch.sub.2 SH, and --NH.sub.2 ; X is selected from the group consisting of (CH.sub.2).sub.m, where m is an integer from 0 to about 10, phenylene, hydroxyl-substituted phenylene, halogen-substituted phenylene, alkyl substituted phenylene or aminated phenylene groups;A is 0, 1 or 2;B is 2-a, with the proviso that there be at least two R groups in the product; andN is a number from 1 to about 100,000The new tool provides higher specific activity for labeled substances thus facilitating determination of the desired compound.

Abstract: The invention relates to an oral pharmaceutical preparation with androgenic activity on the basis of one or more esters of testosterone and/or 5.alpha.-dihydrotestosterone, the ester group of which has been derived exclusively from aliphatic carboxylic acids having 9-16 carbon atoms, preferably 10-12 carbon atoms in combination with a non-steroidal lipoid. The preparation may additionally contain a progestational steroid, an oestrogen or a precursor of an A-aromatic steroid.

Abstract: The invention relates to novel dibenzo?1,2;5,6! cyclophepta pyridine or -pyrrole derivatives, dibenzo?2,3;6,7! oxepino pyridine or pyrrole derivatives, dibenzo?2,3;6,7! thiepino pyridine or pyrrole derivatives and dibenzo?b,f! pyrido or pyrrole azepine derivatives of general formula: ##STR1## as well as the pharmaceutically acceptable salts and nitrogen oxides thereof, whereinR.sub.1, r.sub.2, r.sub.3 and R.sub.4 each represent hydrogen, hydroxy, halogen, an alkyl (1-6 C) group, an alkoxy or alkylthio group in which the alkyl group contains 1-6 C-atoms, or a trifluoromethyl group,R.sub.5 represents hydrogen, an alkyl group with 1-6 carbon atoms or an aralkyl group with 7-10 carbon atoms,M is the number 1 or 2,X represents oxygen, sulphur, the group ##STR2## or the group --CH.sub.2 -- and R.sub.6 represents hydrogen or a lower alkyl group (1-4 C), having CNS-depressant activity and excellent antihistamine and antiserotonin activities.

Abstract: A three-phase method of human female contraception wherein (1) starting on about the ninth to about the twelfth day of the female cycle (first cycle day being first menstruation day) an effective amount of at least one progestagenic substance is administered in daily or shorter intervals for about three to about six days followed at substantially similar intervals by (2) administration for about one to about three days starting from about the fourth to about the seventh day after the first phase of both an effective amount of the progestagenic substance(s), and a peptide possessing LHRF (Luteinizing Hormone Release Factor) activity, followed by (3) administration of an effective amount of the progestagenic substance(s) until the total time of the progestagenic substance administration with and without the LHRF compound is from about seven to about fifteen days.

Abstract: The invention discloses novel compounds of the general formula: ##STR1## and salts thereof, in which X stands for oxygen, sulphur, the group >NR.sub.7 or the group --CR.sub.8 R.sub.9 --;R.sub.1, r.sub.2, r.sub.3 and R.sub.4 represent hydrogen, hydroxy, halogen, alkyl (1-6 C), alkoxy (1-6 C), alkylthio (1-6 C) or trifluoromethyl;R.sub.5 and R.sub.6 represent hydrogen, alkyl (1-6 C), aralkyl (7-10 C) or together in combination with the nitrogen atom a heterocyclic five- or six-membered ring;R.sub.7 stands for hydrogen or alkyl (1-4 C);R.sub.8 and R.sub.9 stand for hydrogen or methyl,n is the number 0, 1 or 2 andThe dotted line means an optional C--C bond,With valuable central nervous system (CNS) activities, especially antidepressant activity.

Abstract: Biologically active novel peptide compounds are disclosed of the formulaA-L-B-D-Lys-L-Phe-Gly-(L or D)Lys-L-Pro-L-Val-Gly-L-Lys-L-Lys-Xor a pharmaceutically acceptable non-toxic functional derivative thereof; A is a N-terminal chain prolongation selected from the group consisting of (1) hydrogen and (2) N-acyl radicals derived from (a) alkyl carboxylic acids having from one to about six carbons, (b) aralkyl carboxylic acids having from seven to about ten carbons, (c) amino acids, (d) peptides, (e) the N-alkylcarbonyl or N-aralkylcarbonyl derivatives of the amino acids, and (f) the N-alkylcarbonyl or N-aralkylcarbonyl derivatives of the peptides; B is an amino-acid residue selected from the group consisting of Phe, Trp, Tyr, and --NH--CHR.sub.1 --CO--, wherein R.sub.1 is hydrogen or alkyl from one to about six carbons; and X is a member selected from the group consisting of hydroxy, esterified hydroxy radicals, unsubstituted amino radicals and substituted amino radicals.

Abstract: The present invention relates to novel biologically active tricyclic compounds of the general formula: ##STR1## and salts thereof, IN WHICHR.sub.1 and R.sub.2 stand for hydroge, alkyl or alkenyl, an optionally substituted aralkyl group or an acyl group orR.sub.1 + r.sub.2 together with the nitrogen atom represent a heterocyclic 5- or 6-membered ring, andX and Y stand for hydrogen, hydroxy, halogen, alkyl or alkoxy of 1-6 carbon atoms, nitro, trifluoromethyl or an acyloxy group,Which compounds have valuable biological activities, particularly anorectic activity.

Abstract: Biologically active novel peptides and peptide-derivatives of the general formula: ##STR1## where A represents H-(L or D)Met, H-(L or D)Met(.fwdarw.O), H-(L or D)Met(.fwdarw.O.sub.2)desamino-Met, desamino-Met(.fwdarw.O),desamino-Met(.fwdarw.O.sub.2) or the group H.sub.2 N--B--CO--;B represents a branched or straight-chain alkylene (C.sub.1 -C.sub.6) or alkylidene (C.sub.1 -C.sub.6) group;Q represents the amino-acid residue --NH--CHR--CO--;R represents alkyl (C.sub.1 -C.sub.6), p-hydroxyphenylmethyl, 3-indolylmethyl or phenylmethyl;R.sub.1 and R.sub.2 represent hydrogen or an alkyl(1-6C) group, andZ represents N-(phenylalkyl)amino, N-(.beta.-indolylalkyl)amino, L-Trp-OH, L-Phe-OH, L-Trp-Gly-OH or L-Phe-Gly-OH, as well as the functional derivatives thereof.

Abstract: The invention relates to compounds of the general formula: ##STR1## in which one double bond is present between the carbon atom of the quanidine moiety and one of the adjacent nitrogen atoms andR.sub.0 stands for hydrogen, halogen, hydroxy, alkoxy or alkyl (1 to 6 C),R.sub.1, r.sub.2 for halogen, hydroxy, alkyl (1 to 4 C) or alkoxy (1 to 4 C),R.sub.3, r.sub.3 ', r.sub.3 " for hydrogen or alkyl (1 to 4 C), on the understanding that one of the substituents R.sub.3, R.sub.3 ' or R.sub.3 " is absent because of the presence of the double bond,R.sub.4 for hydrogen, alkyl (1-4 C), hydroxy, alkoxy (1-4 C) or amino optionally substituted with one or two alkyl (1 to 4 C) groups,R.sub.5, r.sub.6 for hydrogen, alkyl (1-6 C), acyl or R.sub.5 + R.sub.6 together represent an alkylidene, cyclic alkylidene or aralkylidene group, as well as the acid addition salts thereof,Provided that, if R.sub.4 stands for methyl and R.sub.0, R.sub.3, R.sub.3 ", R.sub.5 and R.sub.6 for hydrogen, R.sub.1 and R.sub.

Abstract: The invention relates to an oral pharmaceutical preparation with androgenic activity on the basis of one or more esters of testosterone and/or 5.alpha.-dihydrotestosterone, the ester group of which has been derived exclusively from aliphatic carboxylic acids having 9-16 carbon atoms, preferably 10-12 carbon atoms in combination with a non-steroidal lipoid. The preparation may additionally contain a progestational steroid, an oestrogen or a precursor of an A-aromatic steroid.

Abstract: The present invention relates to a rapid and sensitive method for the determination of a reduced coenzyme, particularly NADH, NADPH and derivatives thereof, in that the fluorescence of such a reduced coenzyme in an aqueous medium is measured in the presence simultaneously of an organic liquid miscible with water and a dipersion of one or more slightly soluble or insoluble substances.

Abstract: The invention relates to novel amidino-hydrazone derivatives of the general formula: ##STR1## in which the dotted lines mean one extra bond starting from the (guanidine-) carbon atom to one of the adjacent nitrogen atoms, andA stands for methylene, ethylene, propylene or butylene, which groups may optionally be substituted with alkyl (1-4 C),R stands for hydroxy, alkyl (1-4 C), alkylthio or alkoxy (1-4 C), halogen, trifluoromethyl, nitro, amino, hydroxymethyl, acyloxy or an alkylenedioxy group,N is the number 0, 1, 2, 3 or 4,R.sub.1, r.sub.4 and R.sub.5 represent hydrogen or alkyl (1-4 C), with the proviso that one of them is absent in view of the presence of the double bond,R.sub.2 and R.sub.3 stand for hydrogen, alkyl (1-4 C), aralkyl, aryl, hydroxy or amino, with the proviso thatR.sub.2 + r.sub.3 together may also represent a saturated or unsaturated alkylene group with 2 or 3 carbon atoms, orR.sub.3 + r.sub.

Abstract: The invention relates to a novel pharmaceutical preparation with oestrogenic activity adapted for oral administration comprising an oestradiol-17.beta.-ester, the ester group of which has been derived from aliphatic carboxylic acids having 9-16 carbon atoms, in combination with a non-steroidal lipoid. The preparation may additionally contain a progestational steroid or an androgen. The invention also relates to novel oestradiol-17.beta.-esters.

Abstract: Disclosed are a reagent and test slide used for serological detection of gonorrheal antibodies in human blood serum or synovial fluid. The reagent comprises latex particles having absorbed on their surfaces an inert protein, such as bovine serum albumin and a heat labile antigen derived from Neisseria gonorrhoeae bacteria exhibiting T.sub.1 colonial morphology. The reagent may be employed by several forms, for example, as a liquid suspension of the latex particles, or in the form of a dried deposit of the latex particles. Regardless of the form employed, the reagent is particularly useful as a routine screening test in hospitals and prenatal clinics to detect gonococcal infection in women and also in cases of complicated gonorrhea, e.g., gonorrheal arthritis where infection is not conveniently detectable by present means. The test slide may have dried thereon an absorbing antigen for heterophile antibodies.

Abstract: The invention relates to compounds of the general formula I: ##STR1## or a salt thereof, in which A represents a pyridine ring or a halogen substituted pyridine ring,R.sub.1 represents hydrogen, alkyl (1-6 C), alkoxy (1-6 C), alkylthio (1-6 C), halogen, OH, SH or CF.sub.3R.sub.2 represents hydrogen or a lower alkyl or aralkyl group andn and m may each be 1, 2 or 3 with the proviso that the sum of m and n must be 2, 3 or 4, having CNS activity, a pronounced antihistamine activity and little or no antiserotonin activity.